A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)

Clinical trial NCT02212730 · TERMINATED

Trial details

NCT number: NCT02212730
Sponsor: Merck Sharp & Dohme LLC
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Renal Cell Cancer

Start date: 2014-12-03
Primary completion: 2019-07-05
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.